Two Cases of Chronic Central Serous Chorioretinopathy Successfully Treated with Systemic Interferon Alpha

References

• van Rijssen TJ, van Dijk EHC, Yzer S, et al. Central serous chorioretinopathy: towards an evidence-based treatment guideline. Prog Retin Eye Res. 2019;73:100770. doi:10.1016/j.preteyeres.2019.07.003.
   PubMed Web of Science ®Google Scholar
• Sartini F, Figus M, Nardi M, Casini G, Posarelli C. Non-resolving, recurrent and chronic central serous chorioretinopathy: available treatment options. Eye (Lond). 2019;33(7):1035–1043. doi:10.1038/s41433-019-0381-7.
   PubMed Web of Science ®Google Scholar
• Daruich A, Matet A, Dirani A, et al. Central serous chorioretinopathy: recent findings and new physiopathology hypothesis. Prog Retin Eye Res. 2015;48:82–118. doi:10.1016/j.preteyeres.2015.05.003.
   PubMed Web of Science ®Google Scholar
• Mrejen S, Balaratnasingam C, Kaden TR, et al. Long-term visual outcomes and causes of vision loss in chronic central serous chorioretinopathy. Ophthalmology. 2019;126(4):576–588. doi:10.1016/j.ophtha.2018.12.048.
   PubMed Web of Science ®Google Scholar
• Wang M, Munch IC, Hasler PW, Prünte C, Larsen M. Central serous chorioretinopathy. Acta Ophthalmol. 2008;86(2):126–145. doi:10.1111/j.1600-0420.2007.00889.x.
   PubMed Web of Science ®Google Scholar
• Carvalho-Recchia CA, Yannuzzi LA, Negrão S, et al. Corticosteroids and central serous chorioretinopathy. Ophthalmology. 2002;109(10):1834–1837. doi:10.1016/s0161-6420(02)01117-x.
   PubMed Web of Science ®Google Scholar
• Yannuzzi LA. Type a behavior and central serous chorioretinopathy. Retina. 2012;32(Suppl 1):709. doi:10.1097/iae.0b013e31823ff9a6.
   PubMedGoogle Scholar
• Schubert C, Pryds A, Zeng S, et al. Cadherin 5 is regulated by corticosteroids and associated with central serous chorioretinopathy. Hum Mutat. 2014;35(7):859–867. doi:10.1002/humu.22551.
   PubMed Web of Science ®Google Scholar
• Miki A, Kondo N, Yanagisawa S, Bessho H, Honda S, Negi A. Common variants in the complement factor H gene confer genetic susceptibility to central serous chorioretinopathy. Ophthalmology. 2014;121(5):1067–1072. doi:10.1016/j.ophtha.2013.11.020.
   PubMed Web of Science ®Google Scholar
• Tsai DC, Huang CC, Chen SJ, et al. Central serous chorioretinopathy and risk of ischaemic stroke: a population-based cohort study. Br J Ophthalmol. 2012;96(12):1484–1488. doi:10.1136/bjophthalmol-2012-301810.
   PubMed Web of Science ®Google Scholar
• Mansuetta CC, Mason JO 3rd, Swanner J, et al. An association between central serous chorioretinopathy and gastroesophageal reflux disease. Am J Ophthalmol. 2004;137(6):1096–1100. doi:10.1016/j.ajo.2004.01.054.
   PubMed Web of Science ®Google Scholar
• Liu HY, Yang CH, Yang CM, Ho TC, Lin CP, Hsieh YT. Half-dose versus half-time photodynamic therapy for central serous chorioretinopathy. Am J Ophthalmol. 2016;167:57–64. doi:10.1016/j.ajo.2016.04.001.
   PubMed Web of Science ®Google Scholar
• Chan WM, Lai TY, Lai RY, Liu DT, Lam DS. Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy: one-year results of a randomized controlled trial. Ophthalmology. 2008;115(10):1756–1765. doi:10.1016/j.ophtha.2008.04.014.
   PubMed Web of Science ®Google Scholar
• Sirks MJ, van Dijk EHC, Rosenberg N, et al. Clinical impact of the worldwide shortage of verteporfin (Visudyne®) on ophthalmic care. Acta Ophthalmol. 2022;100(7):e1522–e1532. doi:10.1111/aos.15148.
   PubMed Web of Science ®Google Scholar
• Robertson DM, Ilstrup D. Direct, indirect, and sham laser photocoagulation in the management of central serous chorioretinopathy. Am J Ophthalmol. 1983;95(4):457–466. doi:10.1016/0002-9394(83)90265-9.
   PubMed Web of Science ®Google Scholar
• van Dijk EHC, Fauser S, Breukink MB, et al. Half-dose photodynamic therapy versus high-density subthreshold micropulse laser treatment in patients with chronic central serous chorioretinopathy: the PLACE trial. Ophthalmology. 2018;125(10):1547–1555. doi:10.1016/j.ophtha.2018.04.021.
   PubMed Web of Science ®Google Scholar
• Rahimy E, Pitcher JD 3rd, Hsu J, et al. A randomized double-blind placebo-control pilot study of eplerenone for the treatment of central serous chorioretinopathy (Ecselsior). Retina. 2018;38(5):962–969. doi:10.1097/iae.0000000000001649.
   PubMed Web of Science ®Google Scholar
• Lee JH, Lee SC, Kim H, Lee CS. Comparison of short-term efficacy between oral spironolactone treatment and photodynamic therapy for the treatment of nonresolving central serous chorioretinopathy. Retina. 2019;39(1):127–133. doi:10.1097/iae.0000000000001913.
   PubMed Web of Science ®Google Scholar
• Chung YR, Kim JW, Song JH, Park A, Kim MH. Twelve-month efficacy of intravitreal bevacizumab injection for chronic, atypical, or recurrent central serous chorioretinopathy. Retina. 2019;39(1):134–142. doi:10.1097/iae.0000000000001917.
   PubMed Web of Science ®Google Scholar
• Kurup SK, Oliver A, Emanuelli A, Hau V, Callanan D. Low-dose methotrexate for the treatment of chronic central serous chorioretinopathy: a retrospective analysis. Retina. 2012;32(10):2096–2101. doi:10.1097/IAE.0b013e31825dd281.
   PubMed Web of Science ®Google Scholar
• Shulman S, Goldenberg D, Schwartz R, et al. Oral Rifampin treatment for longstanding chronic central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol. 2016;254(1):15–22. doi:10.1007/s00417-015-2989-z.
   PubMed Web of Science ®Google Scholar
• Nielsen JS, Jampol LM. Oral mifepristone for chronic central serous chorioretinopathy. Retina. 2011;31(9):1928–1936. doi:10.1097/IAE.0b013e31821c3ef6.
   PubMed Web of Science ®Google Scholar
• Pikkel J, Beiran I, Ophir A, Miller B. Acetazolamide for central serous retinopathy. Ophthalmology. 2002;109(9):1723–1725. doi:10.1016/s0161-6420(02)01157-0.
   PubMed Web of Science ®Google Scholar
• Liew G, Ho I-V, Ong S, Gopinath B, Mitchell P. Efficacy of topical carbonic anhydrase inhibitors in reducing duration of chronic central serous chorioretinopathy. Trans Vision Sci Tech. 2020;9(13):6. doi:10.1167/tvst.9.13.6.
   PubMed Web of Science ®Google Scholar
• Wuarin R, Kakkassery V, Consigli A, et al. Combined topical anti-inflammatory and oral acetazolamide in the treatment of central serous chorioretinopathy. Optom Vis Sci. 2019;96(7):500–506. doi:10.1097/opx.0000000000001394.
   PubMed Web of Science ®Google Scholar
• Kötter I, Zierhut M, Eckstein AK, et al. Human recombinant interferon alfa-2a for the treatment of Behçet’s disease with sight threatening posterior or panuveitis. Br J Ophthalmol. 2003;87(4):423–431. doi:10.1136/bjo.87.4.423.
   PubMed Web of Science ®Google Scholar
• Gueudry J, Wechsler B, Terrada C, et al. Long-term efficacy and safety of low-dose interferon alpha 2a therapy in severe uveitis associated with Behçet disease. Am J Ophthalmol. 2008;146(6):837–44.e1. doi:10.1016/j.ajo.2008.08.038.
   PubMed Web of Science ®Google Scholar
• Diwo E, Gueudry J, Saadoun D, Weschler B, LeHoang P, Bodaghi B. Long-term efficacy of interferon in severe uveitis associated with Behçet disease. Ocul Immunol Inflamm. 2017;25(1):76–84. doi:10.1080/09273948.2016.1206204.
   PubMed Web of Science ®Google Scholar
• Aksu-Ceylan N, Cebeci Z, Altinkurt E, Kir N, Oray M, Tugal-Tutkun I. Interferon alpha-2a for the Treatment of cystoid macular edema secondary to acute retinal necrosis. Ocul Immunol Inflamm. 2022;30(7–8):1788–1797. doi:10.1080/09273948.2021.1957121.
   PubMed Web of Science ®Google Scholar
• Oray M, Onal S, Uludag G, Akbay AK, Tugal-Tutkun I. Interferon alpha for the treatment of cystoid macular edema associated with presumed ocular tuberculosis. J Ocul Pharmacol Ther. 2017;33(4):304–312. doi:10.1089/jop.2016.0097.
   PubMed Web of Science ®Google Scholar
• Invernizzi A, Iannaccone F, Marchi S, et al. Interferon alpha-2a for the treatment of post-infectious uveitis secondary to presumed intraocular tuberculosis. Ocul Immunol Inflamm. 2019;27(4):643–650. doi:10.1080/09273948.2018.1431292.
   PubMed Web of Science ®Google Scholar
• Stiefel HC, Kopplin LJ, Albini T, Chang M, Vegunta S, Suhler EB. Treatment of refractory cystoid macular edema with pegylated interferon alfa-2a: a retrospective chart review. Ocul Immunol Inflamm. 2021;29(3):566–571. doi:10.1080/09273948.2019.1687729.
   PubMed Web of Science ®Google Scholar
• Kawali A, Sanjay S, Mohan A, Mahendradas P, Shroff S, Shetty R. Intensive topical interferon therapy in uveitic macular edema. Indian, J Ophthalmol. 2022;70(8):2986–2989. doi:10.4103/ijo.IJO_3210_21.
   PubMed Web of Science ®Google Scholar
• Deuter CM, Koetter I, Guenaydin I, Stuebiger N, Zierhut M. Interferon alfa-2a: a new treatment option for long lasting refractory cystoid macular edema in uveitis? A pilot study. Retina. 2006;26(7):786–791. doi:10.1097/01.iae.0000244265.75771.71.
   PubMed Web of Science ®Google Scholar
• Deuter CM, Kötter I, Günaydin I, Stübiger N, Doycheva DG, Zierhut M. Efficacy and tolerability of interferon alpha treatment in patients with chronic cystoid macular oedema due to non-infectious uveitis. Br J Ophthalmol. 2009;93(7):906–913. doi:10.1136/bjo.2008.153874.
   PubMed Web of Science ®Google Scholar
• De Simone L, Gentile P, Aldigeri R, et al. Effectiveness of pegylated interferon alpha-2a in post-uveitic macular edema previously responding to non-pegylated interferon. Ocul Immunol Inflammation. 2023;1–5. doi:10.1080/09273948.2023.2195494.
   PubMed Web of Science ®Google Scholar
• Karska-Basta I, Pociej-Marciak W, Chrząszcz M, Kubicka-Trząska A, Romanowska-Dixon B, Sanak M. Altered plasma cytokine levels in acute and chronic central serous chorioretinopathy. Acta Ophthalmol. 2021;99(2):e222–e231. doi:10.1111/aos.14547.
   PubMed Web of Science ®Google Scholar
• Gillies MC, Su T. Interferon-alpha 2b enhances barrier function of bovine retinal microvascular endothelium in vitro. Microvasc Res. 1995;49(3):277–288. doi:10.1006/mvre.1995.1024.
   PubMed Web of Science ®Google Scholar
• Butler NJ, Suhler EB, Rosenbaum JT. Interferon alpha 2b in the treatment of uveitic cystoid macular edema. Ocul Immunol Inflamm. 2012;20(2):86–90. doi:10.3109/09273948.2011.645989.
   PubMed Web of Science ®Google Scholar
• Dimopoulos S, Deuter CME, Blumenstock G, et al. interferon alpha for refractory pseudophakic cystoid macular edema (Irvine-gass syndrome). Ocul Immunol Inflamm. 2020;28(2):315–321. doi:10.1080/09273948.2019.1585883.
   PubMed Web of Science ®Google Scholar
• Mackensen F, Jakob E, Springer C, et al. Interferon versus methotrexate in intermediate uveitis with macular edema: results of a randomized controlled clinical trial. Am J Ophthalmol. 2013;156(3):478–486.e1. doi:10.1016/j.ajo.2013.05.002.
   PubMed Web of Science ®Google Scholar
• Tomer Y, Blackard JT, Akeno N. Interferon alpha treatment and thyroid dysfunction. Endocrinol Metab Clin North Am. 2007;36(4):1051–1066; x–xi. doi:10.1016/j.ecl.2007.07.001.
   Web of Science ®Google Scholar
• Kozielewicz D, Zaleśna A, Dybowska D. Can pegylated interferon α 2a cause development of thyroid disorders in patients with chronic hepatitis B? Expert Opin Drug Saf. 2014;13(8):1009–1014. doi:10.1517/14740338.2014.921156.
   PubMed Web of Science ®Google Scholar
• Renault PF, Hoofnagle JH, Park Y, et al. Psychiatric complications of long-term interferon alfa therapy. Arch Intern Med. 1987;147(9):1577–1580. doi:10.1001/archinte.1987.00370090055011.
   PubMedGoogle Scholar
• Davoodi L, Masoum B, Moosazadeh M, Jafarpour H, Haghshenas MR, Mousavi T. Psychiatric side effects of pegylated interferon-α and ribavirin therapy in Iranian patients with chronic hepatitis C: a meta-analysis. Exp Ther Med. 2018;16(2):971–978. doi:10.3892/etm.2018.6255.
   PubMed Web of Science ®Google Scholar